Previous 10 | Next 10 |
Nutriband ( NASDAQ: NTRB ) announced its approval to dual list its shares on Upstream and NFTs powered by Horizon Fintex and MERJ Exchange Limited. Trading commences on Upstream January 5, 2023 at 10:00am ET under the ticker symbol ‘NTRB.' "Building shareholder v...
Trading to Commence on Upstream January 5, 2023 under Upstream Ticker Symbol NTRB; all Upstream Participants Eligible to Receive Commemorative NFT ORLANDO, FL / ACCESSWIRE / December 14, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) today announced its approval to dual list its shares on...
ORLANDO, FL / ACCESSWIRE / December 5, 2022 / Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced financial and operational results for the third quarter ended October 31, 2022. Key Highlights: Generated record quarterly revenue o...
ORLANDO, FL / ACCESSWIRE / December 2, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) today announces that Gareth Sheridan, CEO, will be presenting at the RHK Capital Disruptive Growth Conference in New York City on Monday, December 5 at 10:20 AM. Mr. Sheridan will present a corporate overvie...
ORLANDO, FL / ACCESSWIRE / December 1, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) announced that the Canadian Intellectual Property Office (CIPO) has granted Canadian patent No. 2,937,649, entitled "Abuse and Misuse Deterrent Transdermal Systems," with an issue date of November 1, 2022. T...
New guidelines reiterate need for abuse deterrent technologies and call for enabling clinicians to provide comprehensive pain management including appropriate use of opioid medications ORLANDO, FL / ACCESSWIRE / November 8, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) supports the ...
ORLANDO, FL / ACCESSWIRE / October 27, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), today announced that it has signed an exclusive manufacturing agreement with Fleur Marché for its CBD and Botanical Patch lines. Nutriband Inc.'s wholly owned contract manufacturing subsidiary, Act...
ORLANDO, FL / ACCESSWIRE / October 26, 2022 / Nutriband Inc. (the "Company") (NASDAQ:NTRB) (NASDAQ:NTRBW) today announced that its subsidiary, 4P Therapeutics LLC ("4P Therapeutics"), has conducted a Phase 1b clinical study for Sorrento Therapeutics, Inc. ("Sorrento") (NASDAQ:SRNE) with resu...
ORLANDO, FL / ACCESSWIRE / October 17, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) ("Nutriband" or the "Company") today announced that it has accepted an invitation as a guest speaker for the 2023 Transdermal and Microneedle Conference to be held in London on January 23 and 24. The Com...
ORLANDO, FL / ACCESSWIRE / October 4, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) with Kindeva Drug Delivery have demonstrated enhanced abuse deterrence kinetics of the Company's patented lead product, Aversa™ Fentanyl, an abuse-deterrent fentanyl transdermal system, with their ...
News, Short Squeeze, Breakout and More Instantly...
Nutriband (NASDAQ: NTRB) , a pharmaceutical company with a special focus on transdermal technologies, is inviting investors to a live webinar. Scheduled for July 25, 2024, at 4:15 p.m. ET, this exclusive event will be hosted by RedChip Companies. During the webinar, Nutriband Chairman and Preside...
ORLANDO, FL / ACCESSWIRE / July 19, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical solutions, is pleased to invite investors to a webinar on July 25, 2024, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Nutriband Cha...
Nutriband (NASDAQ: NTRB) , a developer of transdermal pharmaceutical products, has received a Notice of Allowance from the United States Patent and Trademark Office (“USPTO”). According to the announcement, the notice means that the USPTO anticipates granting the trademark registrat...